Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells-Reference-Cited by-同舟云学术

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells

Published:2018-05 Issue:5 Volume:20 Page:467-477
ISSN:1476-5586
Container-title:Neoplasia
language:en
Short-container-title:Neoplasia

Author:

Mologni Luca,Costanza Mariantonia,Sharma Geeta Geeta,Viltadi Michela,Massimino Luca,Citterio Stefania,Purgante Stefania,Raman Hima,Pirola Alessandra,Zucchetti Massimo,Piazza Rocco,Gambacorti-Passerini Carlo

Funder

Italian Association for Cancer Research

EU Commission

Publisher

Elsevier BV

Subject

Cancer Research

Reference49 articles.

1. How I treat newly diagnosed chronic myeloid leukemia in 2015;Gambacorti-Passerini;Am J Hematol,2015

2. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients;Gambacorti Passerini;J Natl Cancer Inst,2014

3. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer;Krajewska;Expert Rev Clin Pharmacol,2016

4. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat Rev Cancer,2010

5. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

2. Targeting ferroptosis in melanoma: cancer therapeutics;Cell Communication and Signaling;2023-11-23

3. Current understanding of epigenetics role in melanoma treatment and resistance;Cancer Cell International;2022-10-12

4. A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues;Scientific Reports;2022-06-20

5. A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in histologically healthy tissues;2022-03-01